Molecular-genetic and immunological aspects of the formation of psychopathological symptoms in schizophrenia

Close metadata

Recommended articles:

Cerebral hemodynamic disorders in patients with schizophrenia with concomitant metabolic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):80-85

Clinical and psychopathological characteristics of patients with late-onset schizophrenia and schizophrenia-like psychoses in clusters identified by biological parameters. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):137-144

Clinical and psychometric characteristics of cognitive and negative disorders in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):64-71

Features of course of pain syndrome in patients with schwannomatosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):48-52

Controversial issues of diagnosis and theoretical concepts of schizophrenia in childhood. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):17-24

Psychological concepts — design of clinical models of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):25-31

Pharmacotherapy of schizophrenia: clinical and some age-related aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):41-50

Clinical systematics of chronic delusional psychoses in schizophrenia and schizophrenia-spectrum pathology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):65-74

Prolonged and chronic endogenous manic and manic-delusional states (psychopathology, typology, dynamics, clinic). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):75-81

Colorectal cancer and gut microbiota. P.A. Herzen Journal of Oncology. 2024;(2):60-66

The authors present the data indicating that the formation of psychopathological symptoms of schizophrenia is due to complex and diverse genetic factors associated with various functional and metabolic pathways at different stages of ontogenesis. Despite the fact that at present the genetic basis of positive and negative symptoms as the main pathophysiological manifestations of schizophrenia remains largely unknown, the current level of research allows the identification of some common and unique associations for positive and negative disorders. Based on the analysis of the literature, the specificity of the association of genetic variants with negative symptoms of schizophrenia is shown. It has been also suggested that genes of the immune system may be specifically associated with negative symptoms of schizophrenia. The relevance of studying the relationship of immune system genes, in particular, pro- and anti-inflammatory cytokines, with dimensional characteristics of negative symptoms (abulia-apathy and expressive deficit) is substantiated. Studies of this type have not yet been conducted, despite accumulating data indicating that the heterogeneity of negative symptoms is based on different neurobiological mechanisms. It is concluded that the immunological and molecular genetic study of the subdomains of psychopathological symptoms can be promising as part of the transition to deep phenotyping, which seems to be especially relevant for the study of such an extremely heterogeneous disease from a clinical point of view as schizophrenia. The development of this area is important for solving the problems of precision medicine, which aims to provide the most effective therapy for a particular patient by stratifying the disease into subclasses, taking into account their biological basis.

Keywords:

schizophrenia

negative symptoms

genes

inflammation

deep phenotyping

Authors:

Golimbet V.E.

Mental Health Research Center

ORCID: 0000-0002-9960-7114

Klyushnik T.P.

Mental Health Research Center

ORCID: 0000-0001-5148-3864

Received:

17.05.2022

Accepted:

17.06.2022

List of references:

Pillinger T, D’Ambrosio E, McCutcheon RA, et al. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in ﬁrst- episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24:776-794. https://doi.org/10.1038/s41380-018-0058-9
Pardiñas AF, Holmans P, Pocklington AJ, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018 Mar;50(3):381-389. https://doi.org/10.1038/s41588-018-0059-2
van Kesteren CFMG, Gremmels H, de Witte LD, et al. Immune involvement in the pathogenesis of schizophrenia: A meta-analysis on postmortem brain studies. Transl Psychiatry. 2017;7:e1075. https://doi.org/10.1038/tp.2017.4
Marques TR, Ashok AH, Pillinger T, et al. Neuroinﬂammation in schizophrenia: Meta-analysis of in vivo microglial imaging studies. Psychol Med. 2019;49:2186-2196. https://doi.org/10.1017/s0033291718003057
Mongan D, Ramesar M, Föcking M, Cannon M, et al. Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment. Early Interv Psychiatry. 2020;14(4):385-397. https://doi.org/10.1111/eip.12859
Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018;44(5):973-982. https://doi.org/10.1093/schbul/sby024
Gallego JA, Blanco EA, Husain-Krautter S, et al. Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis. Schizophr Res. 2018;202:64-71. https://doi.org/10.1016/j.schres.2018.07.019
Wang AK, Brian J Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;13;44(1):75-83. https://doi.org/10.1093/schbul/sbx035
Kliushnik TP, Zozulya SA, Androsova LV, et al. Immunological monitoring of endogenous attack-like psychoses. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2014;114(2):37-42. (In Russ.).
Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258-270. https://doi.org/10.1016/S2215-0366(14)00122-9
Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology. 2017;42(1):193-215. https://doi.org/10.1038/npp.2016.199
Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules. 2019;24(8):1583. https://doi.org/10.3390/molecules24081583
Klyushnik TP, Smulevich AB, Zozulya SA, Voronova EI. Neurobiology of schizophrenia (to the construction of clinical and biological model). Psykhiatria. 2021;19(1):6-15. (In Russ.). https://doi.org/10.30629/2618-6667-2021-19-1-6-15
Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167(7):763-772. https://doi.org/10.1176/appi.ajp.2009.09040598
Xavier RM, Vorderstrasse A. Genetic Basis of Positive and Negative Symptom Domains in Schizophrenia. Biol Res Nurs. 2017;19(5):559-575. https://doi.org/10.1177/1099800417715907
Wu Q, Wang X, Wang Y, et al. Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia. Neurosci Bull. 2021;37(11):1609-1624. https://doi.org/10.1007/s12264-021-00740-6
Waddington JL, Zhen X, O’Tuathaigh CMP. Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond. Front Pharmacol. 2020;10:1638. https://doi.org/10.3389/fphar.2019.01638
Wen X, Xu X, Luo X, et al. Nucks1 gene polymorphism rs823114 is associated with the positive symptoms and neurocognitive function of patients with schizophrenia in parts of southern China. Psychiatr Genet. 2021;31(4):119-125. https://doi.org/10.1097/ypg.0000000000000285
Tovilla-Zárate CA, Vargas I, Hernández S, et al. Association study between the MDR1 gene and clinical characteristics in schizophrenia. Braz J Psychiatry. 2014;36(3):227-232. https://doi.org/10.1590/1516-4446-2013-1270
Golimbet V, Alfimova M, Abramova L, et al. Arginine vasopressin 1a receptor RS3 promoter microsatellites in schizophrenia: a study of the effect of the «risk» allele on clinical symptoms and facial affect recognition. Psychiatry Res. 2015;225(3):739-740. https://doi.org/10.1016/j.psychres.2014.11.043
Bang MJ, Kang JI, Kim SJ, et al. Reduced DNA methylation of the oxytocin receptor gene is associated with anhedonia-asociality in women with recent- onset schizophrenia and ultra-high risk for psychosis. Schizophr Bull. 2019;45:1279-1290. https://doi.org/10.1093/schbul/sbz016
Gao J, Yi HW, Tang XW, et al. DNA methylation and gene expression of matrix metalloproteinase 9 gene in deficit and non-deficit schizophrenia. Front Genet. 2020;11:823. https://doi.org/10.3389/fgene.2018.00646
Rampino A, Torretta S, Gelao B, et al. Evidence of an interaction between FXR1 and GSK3β polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics. Eur Psychiatry. 2021;64(1):e39. https://doi.org/10.1192/j.eurpsy.2021.26
Frydecka D, Misiak B, Pawlak-Adamska E, et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. Eur Arch Psychiatry Clin Neurosci. 2015;265(6):449-459. https://doi.org/10.1007/s00406-014-0533-5
Chen C, Tan B, Zhou Y, et al. IL-28B genetic variant is associated with the risk of schizophrenia in the Chinese Han population. DNA Cell Biol. 2012;31(6):988-992. https://doi.org/10.1089/dna.2011.1471
Garcia-Rizo C, Fernandez-Egea E, Oliveira C, et al. Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res. 2012;198:212-215. https://doi.org/10.1016/j.psychres.2011.08.014
Fabbri C, Serretti A. Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics. 2017;174(7):757-764. https://doi.org/10.1002/ajmg.b.32577
Edwards AC, Bigdeli TB, Docherty AR, et al. Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes. Schizophr Bull. 2016;42(2):279-287. https://doi.org/10.1093/schbul/sbv119
Arnedo J, Svrakic DM, Del Val C, et al. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am J Psychiatry. 2015;172(2):139-153. https://doi.org/10.1176/appi.ajp.2014.14040435
Smulevich AB, Lobanova VM, Voronova EI. History and current state of the problem of negative disorders (research of nosological period). Zh Nevrol Psikhiatr Im S.S. Korsakova. 2021;121(2):122-130. (In Russ.). https://doi.org/10.17116/jnevro2021121021122
Ahmed AO, Strauss GP, Buchanan RW, et al. Are Negative Symptoms Dimensional or Categorical? Detection and Validation of Deficit Schizophrenia With Taxometric and Latent Variable Mixture Models. Schizophr Bull. 2015;41(4):879-891. https://doi.org/10.1093/schbul/sbu163
Kirkpatrick B, Mucci A, Galderisi S. Primary, Enduring Negative Symptoms: An Update on Research. Schizophr Bull. 2017;43(4):730-736. https://doi.org/10.1093/schbul/sbx064
Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58:165-171. https://doi.org/10.1001/archpsyc.58.2.165
Liemburg E, Castelein S, Stewart R, et al. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts, J Psychiatr Res. 2013;47:718-725. https://doi.org/10.1016/j.jpsychires.2013.01.024
Stanculete MF, Capatina O. The Many Faces of Negative Symptoms in Schizophrenia. In: Fukao K, editor. Psychosis — Phenomenology, Psychopathology and Pathophysiology [Internet]. London: IntechOpen; 2021 Aug 09. Available from: https://doi.org/10.5772/intechopen.98412
Mak M, Misiak B, Frydecka D, et al. Polymorphisms in immune-inflammatory response genes and the risk of deficit schizophrenia. Schizophr Res. 2018;193:359-363. https://doi.org/10.1016/j.schres.2017.06.050
Strauss GP, Horan WP, Kirkpatrick B et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res. 2013;47(6):783-790. https://doi.org/10.1016/j.jpsychires.2013.01.015
Be`gue I, Kaiser S, Kirschner M. Pathophysiology of negative symptom dimensions of schizophrenia — Current developments and implications for treatment. Neurosci Biobehav Rev. 2020;116:74-88. https://doi.org/10.1016/j.neubiorev.2020.06.004
Barnes TR, Leeson VC, Paton C, et al. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Health Technol Assess. 2016;20(29):1-46. https://doi.org/10.3310/hta20290
Goldsmith DR, Haroon E, Miller AH, et al. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res. 2018;199:281-284. https://doi.org/10.1016/j.schres.2018.02.048
Krynicki CR, Dazzan P, Pariante CM, et al. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain Behav Immun. 2021;91:498-504. https://doi.org/10.1016/j.bbi.2020.10.026
Roomruangwong C, Noto C, Kanchanatawan B, et al. The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia. Mol Neurobiol. 2020;57(2):778-797. https://doi.org/10.1007/s12035-019-01737-z
Golimbet VE, Romanov DV, Lezheiko TV, et al. A search for genetic variations associated with negative symptoms of schizophrenia. European Psychiatry. 2020;63(S1):S407. https://doi.org/10.1192/j.eurpsy.2020.6
Lynall M, Soskic B, Schwartzentruber HJJ, et al. Genetic variants associated with cross-disorder and disorder-specific risk for psychiatric disorders are enriched at epigenetically active sites in peripheral lymphoid cells. medRxiv preprint. 2021 August 8. https://doi.org/10.1101/2021.08.04.21261606
Handunnetthi L, Saatci D, Hamley JC, et al. Maternal immune activation downregulates schizophrenia genes in the foetal mouse brain. Brain Commun. 2021;3(4):fcab275. https://doi.org/10.1093/braincomms/fcab275
Robinson PN. Deep phenotyping for precision medicine Hum Mutat. 2012;33(5):777-780. https://doi.org/10.1002/humu.22080

Close metadata